消痰化瘀中药对NAFLD大鼠LXRα mRNA和ABCA1表达的影响∗

摘要

Objective:to observe the effect of Chinese Xiaotan Huayu medicine on LXRαmRNA and ABCAI expressions of rats with NAFLD, and to explore its mechanism. Methods: SD rats were randomly divided into control group, model group, Dongbao Gantai group, high-dose, medium-dose and low-dose Chinese medicine groups, administrated with corresponding drugs while models being in-duced. 8 weeks later, detect TC, TG, HDL, LDL, FFA in serum and TC, TG content in hepatic tissue, and observe LXRαmRNA and ABCA1 expressions, and the changes of hepatic histomorphology. Results:Xiaotan Huayu medicine could decrease the content or activity of TC, TG, FFA, ALT and AST, facilitate the LXRαmRNA and ABCA1 expressions increasing, and improve the pathological changes of hepatic tissues. Conclusion:Regulating related gene of LXRα/ABCA1 access and promoting hepatic lipid metabolism may be one of the target points of treating NAFLD with Chinese medicine.%目的：：观察消痰化瘀中药对非酒精性脂肪肝(NAFLD)大鼠脂质代谢和肝脏LXRα和ABCA1mRNA表达的影响，探讨其作用机理。方法：随机将SD雄性大鼠分正常对照组、模型对照组、东宝肝泰对照组以及消痰化瘀中药高、中、低剂量组，一边造模一边灌胃给予相应药物。用药8周后，检测各组大鼠血清TC、 TG、 HDL、LDL、 FFA和肝组织中TC、 TG的含量改变，并观察肝组织LXRα mRNA和小肠ABCA1表达变化以及肝组织形态学的变化。结果：消瘀化痰中药能降低模型大鼠TC、 TG、 FFA、 ALT、 AST的含量或活性，促使LXRα mRNA和ABCA1的表达上调，改善肝组织的病变程度。结论：调控LXRα/ABCA1通路相关基因，促进肝脏脂质代谢，可能是消痰化瘀中药对NAFLD的治疗作用靶点之一。